Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Nice 118k buy EOD.
When's Joe going to let Henry start handling the interviews?
September 25th, 2014 - 0 comments - Filed Under - by John Miller
22nd Century Group (NYSE:XXII) was the recipient of a significant growth in short interest in September. As of September 15th, there was short interest totalling 3,743,602 shares, a growth of 27.0% from the August 29th total of 2,948,406 shares, AnalystRatingsNetwork reports. Based on an average trading volume of 448,374 shares, the days-to-cover ratio is presently 8.3 days. Currently, 9.7% of the shares of the stock are short sold.
22nd Century Group (NYSE:XXII) traded down 0.75% during mid-day trading on Wednesday, hitting $2.63. 413,300 shares of the company’s stock traded hands. 22nd Century Group has a 52 week low of $0.87 and a 52 week high of $6.36. The stock has a 50-day moving average of $2.8 and a 200-day moving average of $2.99. The company’s market cap is $154.5 million.
22nd Century Group, Inc (NYSE:XXII) through its subsidiary, 22nd Century Limited, LLC (22nd Century Ltd), which is a plant biotechnology company.
I would hope a more detailed announcement is on the horizon to provide clarity to what exactly is being researched. My guess is we should hear this announcement when they make their scheduled payment that was mentioned in the 10k.
Upon certain milestones to be achieved by the Investee, which are expected prior to September 30, 2014, the Company will make an additional investment in the Investee in the amount of $450,000 in return for (i) an additional fifteen percent (15%) equity interest in the Investee, and (ii) a worldwide license agreement to the Intellectual Property, including an exclusive license agreement within the U.S. In addition, upon the achievement of the milestones, the Company will grant 150,000 shares of the Company’s common stock to the Investee.
Take a look at the small print at the bottom of that article. What is botanical gardens all about you ask?
Goodrich Tobacco is focused on commercial tobacco products and potential less harmful cigarettes. Botanical Genetics is focused on natural, safe and effective cannabis-based products for human health, well-being and nutrition, in addition to industrial products refined from cannabis. Hercules Pharmaceuticals is focused on X-22, a prescription smoking cessation aid in developm
Mike,
When did you receive that email? Curious if it was recently. Thanks!
Today? Highlights?
June should be fun. Materials News + Bullish Chart = $$$
Don't look now, but 22nd Century Group Inc. (NYSEMKT:XXII) isn't dead after all. It would have been easy to come to that conclusion a month ago, in the shadow of a 66% tumble for XXII shares. In retrospect though, it's relatively easy to see that at least a good portion of the pullback stemmed from the fact that 22nd Century Group was the beneficiate of am exaggerated runup between December and early March.
For those not familiar with it, 22nd Century Group Inc. is a cigarette company... essentially. XXII is better known (so far) for its work in smoking cessation. The company's technology allows tobacco plants to be grown with less nicotine than would normally be present in the plant. The company is also the developer of X-22, which is - or will be - a prescription-based smoking cessation drug. The company drove very little revenue up until the fourth quarter of last year. That's when a licensing deal worth about $7 million in revenue first paid off. Presumably, that licensing revenue is renewable every year.
It's that revenue that likely sparked the rally from a price of $1.15 per share in October of last year to a peak of $6.36 by mid-March of this year for XXII, though moving from an OTC exchange to an NYSE exchange certainly didn't hurt matters either. As is so often the case though, the market didn't realize 22nd Century Group shares were racing out of control - a 450% gain in about five months - until it was too late. The pullback was just as dramatic, and almost as painful. The stock lost 2/3 of its value between mid-March and mid-April.
Great, but what does any of that have to do with 22nd Century Group Inc. now? In simplest terms, the truth (aka the "right price") is somewhere in the middle. The return to that middle represents a bit of a trading opportunity.
Perhaps even more important, XXII has made good on a reversal effort that's been in the making for a while. The bleeding stopped in early May, with the beginning of higher lows and higher highs. That effort was underscored today when 22nd Century Group shares popped back above a coupe of key moving average lines.
The jump was superficially sparked by news that the company was going to build a nicotine-free cigarette production facility in Europe, but truth be told, the move's been developing for weeks now. That's why it could also last for weeks now that it's underway. Though traders can still expect choppiness from XXII (if for no other reason than to fill in today's opening gap), the hard part's been done - the stock is back in bullish mode. A return to a price between $4.00 and $4.50 is likely... maybe more.
Thank-you
Can someone post the cc info? Thanks
I'm on the sidelines as I don't have full access but it's looks like some huge buys. With such a small float wouldn't we be moving much higher with a 60k buy?
So is the 8k the official extension to purchase NASCO by Sept 1st 2014 instead of the end of May?
Thank you
Can you post a link to the article? I'm having trouble locating it.
Much appreciated
I rarely post on the message boards, but due to the recent drama I feel compelled to share my opinion on the situation. First and foremost, I look at everything that unfolded on fri as a non issue. HTFBS and DSNY both confirmed that they were not aware of the pumps and dumps issue. Van recommended DSNY over a year ago and even with the recent plummet of SP the stock has still outperformed the market over that time span. Unfortunately, I got caught with my hand in the cookie jar with DSNY like others here. I bought 1880 @ $2 and at this point will wait to see how the Meeting plays out. HTFBS provides an invaluable service to their subs with picks that most of us would never uncover and provides DD in a way that we can comprehend. I came across XXII back in Feb of 2013 and started investing as I thought this was investment of a lifetime. I searched the web and tried to DD beyond the companies website with no real success. I came across Van and the HTFBS team as they were the only ones who we're providing any information on XXII. I spent the next 7 months validating if I could trust my hard money with his recommendation and information. I can say that not only do I trust their information and recommendation they release, but I look at this service as a potential to be a life changer as some of the other posters have mentioned. I too am also grateful for SPIHF as their technology will change the technology industry for years to come. Thanks to Van and the team I averaged 40340 shares of XXII @ .68, 2300 shares of SPIHF @ $4.30 (wish I had more funds at the initially recommended price of $1 or so) and 1880 DSNY @ $2. This portfolio has been life changing and I hope it continues.
Thanks HTFBS! Keep it up.
Imagine smoking a marijuana cig that had the effects of drinking one beer. If what Perker says is true XXII would have the technology to play in another multi billion dollar market.
Please correct me if I'm wrong but the only reason we would need the FDA approval is to label the package modified risk. We do not need the FDA approval to sell them. The smokers who are looking for these alternative cigarettes will buy them and they make up the 50 billion dollar US market
Big institutions are putting pressure on the price as we near the SHM. Once it's confirmed that there is an agreement they'll buy large blocks at extremely low prices. IMO . This is what happens when you want to play with the big boys. XXII has done everything they can to ensure investors they will meet their obligations stated in June 10th press release. We just need to hold tight and don't panic.
It's looking like the market is agreeing with you. Anyone else want to take a gander on XXII stock price a week from today?
Lets have some fun as we await this major announcement. What do you think the stock price will be one week after the SHM? I'm going to say $2.16. Anyone else care to state their prediction.
Does anyone else find it interesting that there hasn't been one trade this morning?
Can anyone give any insight as to why xxii can't seem to get some upward movement going? You'd think it would at least slowly tick up with the anticipation of the worldwide agreement.
Ztockings - July 27th 2013
Here's another recent article on another modified risk product from RJ Reynolds that is not doing well.
http://www.journalnow.com/business/business_news/local/article_9d001b58-f9f2-11e2-8fad-0019bb30f31a.html
A common factor in all these articles is the FDA is on the fence with the good and the bad that each product brings. There not really putting their support behind any of these products. In XXII case they are working with the FDA and when their products are approved they will have the backing of the FDA. i have to think any major tobacco company would be salivating at the chance to get their hands on a product that has the support of the FDA. That's some powerful stuff!
Not sure if this has been posted but wanted to share a recent article about e-cigs.
E-cigs debate takes turn: Expert says they may pose less risk than cigarettes
Richard Craver/Winston-Salem Journal
The debate about the potential societal benefit of electronic cigarettes has taken an interesting turn with a former Food and Drug Administration advisor saying they “likely pose” a reduced-risk option to traditional cigarettes.
Dr. Neal Benowitz, who served on the FDA’s Tobacco Products Scientific advisory committee, co-authored a July 15 report on e-cigs posted on the Journal of the American Medical Association’s website.
E-cigs are battery-powered devices that heat a liquid nicotine solution in a disposable cartridge and create a vapor that is inhaled.
Bonnie Herzog, an analyst with Wells Fargo Securities, projected $2 billion in retail sales for e-cigs this year and to exceed $10 billion in annual sales by 2017.
Benowitz said e-cigs “likely pose less direct hazard to the individual smoker than tobacco cigarettes and might help smokers quit smoking or reduce harm by smoking fewer tobacco cigarettes.”
“On the other hand, there are potential harms, including promoting continued smoking of cigarettes and renormalizing cigarette smoking behaviors.”
Benowitz’s acknowledgement of the potential public-health benefit of e-cigs is noteworthy considering he is serving on a Pfizer smoking cessation medication advisory board, and has been a consultant to two other pharmaceutical companies. Analysts have said e-cigs, particularly those made by large tobacco manufacturers, could prove stiff competition for the pharmaceutical nicotine-replacement therapy products if given FDA approval.
The FDA was given oversight of the tobacco industry by Congress in 2009, but it cannot ban nicotine or tobacco. It said in 2011 it would determine whether to regulate e-cigs as a tobacco product.
The FDA’s Center for Tobacco Products is charged with evaluating applications for new “modified risk” tobacco products. Products that could fit in that category include R.J. Reynolds Tobacco Co.’s Camel dissolvable orbs, film strips and sticks, the Zonnic nicotine-replacement therapy (NRT) product and the Vuse vapor cigarette.
A company that wants to market a lower-risk tobacco product in the United States must offer scientific proof to the FDA that the marketing of the product will not only reduce harm to individual users, but also benefit the health of the population as a whole.
In April, the FDA said it is no longer putting limits on how long someone trying to quit smoking can use a nicotine-replacement therapy product, such as gum or a patch. The agency said it is removing warnings, as well as limitations in directions, to allow flexibility in how the products are used and for how long.
“Currently available NRT products are not as satisfying and are less acceptable to smokers compared with inhaling and absorbing nicotine from cigarette smoke,” Benowitz said. “The possibility of an inhaled clean-nicotine device has been discussed by health researchers for many years as a potentially more effective way to promote smoking cessation.
“Although not yet proven safe or effective for smoking cessation, the e-cigarette has been positioned as such an inhaled nicotine delivery device and has gained popularity through this perception.”
Benowitz said there are more than 250 e-cig brands in the marketplace.
“Different e-cigarette brands are engineered differently, affecting the character and potential toxicity of the vapor,” he said. “Thus, it is difficult to generalize about e-cigarettes as a single device.”
A regulatory challenge, in the United States and in Europe, has been how to regulate e-cigs – as a medication or a tobacco product. If the FDA determines e-cigs can be helpful in smoking cessation, they could be regulated both ways.
Benowitz said dual regulation for e-cigs makes little practical sense. “A comprehensive regulatory approach to nicotine-containing products is needed,” he said.
The reaction to Benowitz’ report was mixed, with many analysts saying he either went too far or not far enough in evaluating the potential public-health aspects of e-cigs.
“It is good to see Benowitz join the growing number of academicians and scientists who acknowledge the obvious harm-reduction benefits of e-cigarettes and recognize that pharmaceutical-style regulation would stifle critical innovation,” said Carl Phillips, scientific director of the Consumer Advocates for Smoke-free Alternatives Association.
“Unfortunately, they stop short of acknowledging that the innovation matters because people like using e-cigarettes, and innovation contributes to this benefit in addition to improving the safety of the product.”
John Spangler, a professor of family and community medicine at Wake Forest School of Medicine, supports developing and marketing products that lessen exposure to tobacco, including e-cigs if they can be proven scientifically to play that role.
However, he said he is concerned about how e-cigs are being advertised.
“E-cigs might normalize or glamorize smoking because e-cigs look like regular cigarettes, and people will see others/celebrities ‘smoking’ them,” Spangler said.
“It might increase nicotine addiction and decrease cessation – act as a bridge product until a smoker can get to a place where combustible smoking is allowed.”
Brad Rodu, a professor of medicine at the University of Louisville and a smokeless-tobacco advocate, said it is important to note Benowitz said the levels of toxicants in e-cigs “are orders of magnitude lower than those found in cigarette smoke.”
Still, he said hyping the potential risk of e-cigs as a gateway to traditional cigarettes and other tobacco products, as well as dual use of e-cigs and cigarettes, is “unsubstantiated and hypothetical.”
“They represent a distortion of the precautionary principle: e-cigarettes must be heavily regulated by the FDA because they are not proven to be safe and effective. Meanwhile, cigarettes are killing 1,205 Americans. Every. Single. Day.”
Scott Ballin, past chairman of the Coalition on Smoking or Health, said the monitoring and surveillance of new tobacco products should be done jointly by the FDA, manufacturers, the research community and others.
“We should be encouraging innovation and the development of new low-risk products, not suppressing them,” Ballin said.
“The public needs and deserves access to these products. Not making these products available under a regulated system could be a public health disservice.”
rcraver@wsjournal.com
(336) 727-7376
I couldn't agree more and had those same thoughts. Investors are probably waiting to see some actual revenue come in first.
Van, great newsletter this month. Can you explain the benefit of a spin off for xxii if that was to happen for us shareholders?
Has anyone seen this article before? Did this potentially deal fall apart or is it still relevant?
22nd Century Announces Nicotine-Free Tobacco Cigarettes Now Available For International Markets
09-02-2012 09:52 AM
CLARENCE, NEW YORK, UNITED STATES
22nd Century Group, Inc. (OTCBB: XXII), a company focused on tobacco harm reduction and smoking cessation products, today announced that its subsidiary, Goodrich Tobacco Company, is making two of its proprietary cigarette brands (and related tobacco blends) available to licensees and distributors outside the United States.
In response to numerous inquiries from around the world, Goodrich Tobacco is offering MAGIC® EXPORT the world’s only virtually nicotine-free tobacco cigarette and MOONLIGHT™, a cigarette with exceptionally low “tar” per milligram of nicotine, to international partners. As an initial part of this effort, 22nd Century has signed a confidential letter-of-intent for an exclusive agreement to market the company’s technology, brands and tobacco blends in India.
22nd Century’s technology allows for the level of nicotine in the tobacco plant to be decreased or increased through genetic engineering and plant breeding. For example, one of the company’s proprietary tobacco blends has the world’s lowest nicotine content: 97% less nicotine than tobacco in “light” cigarettes. MAGIC® EXPORT virtually nicotine-free cigarettes look, smoke, and taste like conventional cigarettes. MOONLIGHT™ cigarettes contain a proprietary tobacco blend resulting in a nicotine yield of a full-flavor cigarette, but a “tar” yield of a “light” cigarette.
22nd Century has contracted directly with American farmers since 2008 to grow its proprietary tobacco. Previously reported independent research studies have fueled demand for virtually nicotine-free cigarettes (also referred to as very low nicotine or VLN cigarettes), and since the company has now harvested sufficient levels of tobacco leaf to export its products, 22nd Century decided the time is right to commence international distribution.
22nd Century’s technology and tobacco are patented in 79 countries, including the top tobacco markets of the U.S., China, Japan, Russia, Germany, Spain, United Kingdom, Italy, France, Indonesia, South Korea and Brazil. Approximately 6 trillion cigarettes (300 billion packs of 20) were sold globally in 2011. Over the next five years, cigarette industry volume is projected to increase by approximately 1% per year.
Henry Sicignano III, president of Goodrich Tobacco, explained, “Based on inquiries we receive, there is demand for our brands in practically every country, especially for nicotine-free tobacco cigarettes which simply do not exist outside the United States.” Accordingly, 22nd Century believes that MAGIC® EXPORT and MOONLIGHT™ will achieve meaningful share in the global cigarette market among smokers who are interested in alternative products.
To become an exclusive licensee, import agent or distributor, on a country-by-country basis, please send inquiries to info@GoodrichTobacco.com.
For additional information on 22nd Century Group, please visit: www.xxiicentury.com
Cautionary Note Regarding Forward-Looking Statements: This press release contains forward-looking information, including all statements that are not statements of historical fact regarding the intent, belief or current expectations of the company, its directors or its officers with respect to the contents of this press release. The words “may,” “would,” “will,” “expect,” “estimate,” “anticipate,” “believe,” “intend” and similar expressions and variations thereof are intended to identify forward-looking statements.
I came across this article that was released in March 2013 that could give some insight on who the partner is in the worldwide agreement.
http://www.businessweek.com/news/2013-03-18/philip-morris-approaches-decision-on-lower-risk-cigarette-plant
Will we still be able to follow it on ihub?
Let's not forget about the worldwide agreement that should be announced within the month.
I think with the news we've been hearing and if everything goes as plan we could see a market cap around 360 million which would put the stock at $10. That would be my target price, but the sky is the limit and depending on momentum could go higher. This is probably 2-3 years out.
Thanks Sons!
Is there any where to verify that? That would be fantastic.
Tomorrow will tell. We'll see what the rest of the investors think of that move, but that wasn't the vote of confidence that I was looking for.
You'd think if the stock was about to double he'd hold onto those. Very interesting.
Good point. It is about the Big picture where the FDA doesn't oversee. The FDA approval would only sweeten the pot. After additional readings in other articles these other rejected products were submitted under SE pathway or substantial equivalence pathway. I would imagine 22 century would full under a different category like modified risk. Appreciate the post Van!
This could be scary if 22 Century was one of these companies.
"The FDA said that in addition to authorizing Lorillard's products, it also rejected four from companies it declined to name, saying they had not proved their products were substantially equivalent to marketed products."
Nice volume today. Would like to get over half a mil
Came across this article and i thought i would share with the group. I to think this stock has so much potential but wonder how it can trade so low. I think it just comes down to the fact that this company hasn't laid down a solid financial foundation yet. Once some real revenue is put on the books they will come.
http://articles.thehotpennystocks.com/the-hype-surrounding-22nd-century-group-inc-otcbbxxii/